Malaysia
Search
Sign In
Rheumatology
Top Medical News
For patients on glucocorticoid therapy, a delay in anti-osteoporosis treatment initiation may lead to increased fracture events, while early treatment helps to prevent them, a study has found.
Moderate physical activity (PA) appears to help in reducing the risk of hyperuricaemia, according to a study in a multiethnic Chinese population. In addition, decreasing sedentary time (ST) appears to be more beneficial in women than in men.
In patients with Takayasu arteritis, calculating the carotid intima-media thickness (IMT)/diameter ratio (IDR) and peak systolic velocity (PSV) may be useful in identifying neurological severe ischaemic events (SIEs), suggests a study.
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
Treatment with tumour necrosis factor inhibitors (TNFis) in patients with early axial spondyloarthritis (axSpA) appears to put brakes on radiographic sacroiliitis progression, according to a study.
A Singapore study has found an association between the presence of anti-DFS70 and a false-positive antinuclear antibody (ANA) test in 8.6 percent of its patients. Moreover, anti-DFS70 shows no association with the absence of systemic autoimmune rheumatic disease (SARD).
Musculoskeletal pain is a common coexisting symptom in patients with type 2 diabetes (T2D), with most patients having knee or lower back pain, a study reports. However, despite the major disability burden associated with these types of pain, it does not seem to get in the way of achieving treatment targets.
Special Reports
Esflurbiprofen 40 mg transdermal patch
Upadacitinib 15 mg XR-FC tab
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.
Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).
Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.
Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.
